Neurome, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurome, Inc.
SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal
After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
Pfizer And ProFound Partner On Next-Generation Obesity Drugs
Deal Snapshot: Pfizer will collaborate with the Flagship Pioneering-backed startup under a broader long-term partnership between the big pharma and venture capital firm.
Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy
Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice